Pulsenmore 2025: The GE Settlement Cleaned Up the P&L, but the Proof Year Starts Now

Getting To Know The Company

Pulsenmore is not just another medical device name selling a distant concept. It has a commercial product, a real anchor customer in Israel, an FDA clearance that finally opened the U.S. market at the end of October 2025, and a balance sheet that can still finance a meaningful commercialization test. What misleads on a first read is that 2025 looks like an inflection year. That is not the right reading.

This is the core point. Pulsenmore finished 2025 with NIS 40.0 million of revenue and a total comprehensive loss of only NIS 15.9 million, but NIS 30.5 million of that revenue came from the GE settlement. Ongoing revenue, excluding the GE component, was only NIS 9.48 million, slightly below NIS 9.66 million in 2024. Anyone looking only at the top line and the smaller loss could conclude that commercialization has already started to scale. In reality, the report mostly marks the closing of an old accounting and legal chapter, not a new operating proof point.

What is working today? The core product, Pulsenmore ES, is already generating real activity. Clalit and Sheba together produced more than NIS 9.1 million of ES sales in Israel in 2025. ES received FDA clearance as a Class II device, management is already presenting 2026 as the U.S. commercial launch year, and after year end the company signed two service agreements with medical centers in the U.S. At the same time, FC moved from a feasibility study toward a first commercial framework with Clalit. So there is a real operating base here, not just patents and slides.

But the bottleneck is active and obvious: Pulsenmore still lives with extreme customer concentration, international commercialization that is not yet proven, and a balance sheet that is eroding much faster than ongoing revenue is building. Cash and short-term deposits fell from NIS 104.0 million at the end of 2024 to NIS 69.1 million at the end of 2025, and cash flow from operations was still negative NIS 32.9 million. With a market cap of roughly NIS 67.2 million and daily turnover of about NIS 228 thousand, even a better thesis would still come with a practical actionability constraint. That is why 2026 looks like a proof year, not a breakout year.

Pulsenmore’s current economic map is simpler than the presentation may suggest:

One more framing point matters: the company had 63 full- or part-time employees as of mid-March 2026, 51 of them in Israel. This is not a lean platform already harvesting scale. It is still a commercialization story building product, regulation, channels, and payment logic at the same time.

Events And Triggers

First trigger: August 2025 closed the GE chapter, but it did not create a new market by itself. The settlement resolved the dispute over the canceled 15,000-unit order, terminated the component agreement, and left Pulsenmore with both the $1 million advance and the ownership of the purchased components. Beyond that, the company recognized another NIS 23.4 million of revenue because it concluded that the exercise of GE’s remaining distribution rights had become remote. That clearly improves strategic freedom, removes GE’s favored pricing mechanism, and takes Japan out of the exclusive territory, but it does not create fresh demand.

Second trigger: the FDA clearance at the end of October 2025 materially changes the opportunity set. For the first time, the main product has a real path into the U.S. market. In the 20-F, management explicitly says the primary strategic focus is the United States, and in the March 2026 presentation it frames 2026 as the U.S. commercial launch year. After year end, the company also signed two service agreements with U.S.-based medical centers for one-year terms with automatic renewal. This is not scale proof yet, but it does change the next checkpoints the market should monitor.

Third trigger: Clalit remains both the engine of the present and the center of risk. In October 2024 the company signed a new five-year ES agreement for at least 25,000 units, with paid support services and an option for synchronous clinician-guided use. On the other side, in January 2026 it also signed an updated FC commercialization framework: an 18-month pilot period and then five years with a 2,000-unit annual minimum. That is encouraging, but both still sit on the same commercial axis.

Fourth trigger: outside Israel the picture is much more mixed. In Italy, Pulsenmore signed a distribution agreement in 2024 with an initial first-year commitment of about EUR 400 thousand, but as of year end only 120 units had been ordered and the execution date had been postponed. In Australia, the company signed an MOU with a university medical center, and by the end of 2025 100 units had already been ordered and supplied. That tells you there are real openings, but also that non-Israeli commercialization is still uneven.

Efficiency, Profitability And Competition

The key insight is that 2025 profitability looks much better than the underlying business actually delivered. Reported gross profit jumped to NIS 33.7 million, but the main reason was the one-off NIS 30.5 million GE settlement component. Without it, gross profit from the ongoing business would have been roughly NIS 3.1 million, slightly below NIS 3.6 million in 2024. Put differently, the business itself did not inflect.

That gap becomes even clearer when you look at revenue composition. In 2025 Israel generated NIS 9.09 million of ongoing revenue, Europe only NIS 0.19 million, and the rest of the world NIS 0.21 million. Of ongoing revenue, 95.8% came from Israel, and Clalit alone contributed NIS 8.82 million. That is not broad international penetration. It is an Israeli medtech company with an open U.S. option.

The cost base tells a similar story. R&D expense fell 13.4% to NIS 17.4 million, mainly because of lower headcount and grant effects, while sales and marketing rose 14.6% to NIS 11.8 million and G&A rose 9.2% to NIS 16.7 million. The company is easing off one layer of development spend after a certain trial stage, but it is still expanding the commercialization and overhead layer before new revenue is carrying the load.

What matters here is the contradiction between the marketing story and the current revenue base. In the March 2026 presentation, management already frames the U.S. model around 60% device sales and 40% recurring SaaS and monitoring revenue. Strategically that makes sense. But the 20-F itself says service revenue was insignificant during the reporting periods. So the target model is visible, but the numbers do not yet prove that the model is forming.

On the positive side, the product itself does not read like science fiction. The company cites more than 220,000 home scans performed so far, 98.1% of scans suitable for clinical evaluation, and 90% of Clalit survey users reporting lower pregnancy-related stress. It also states that, to its knowledge, there are currently no approved or commercial remote home-use ultrasound solutions designed for patient self-scanning. That is a real product and regulatory advantage. The problem is that such an advantage is worth much less as long as the commercial channel remains narrow.

Cash Flow, Debt And Capital Structure

To understand Pulsenmore, it is better to look here through an all-in cash flexibility lens rather than through the accounting loss alone, meaning how much cash is really left after actual cash uses. On that basis, 2025 was much weaker than the P&L suggests.

At the end of 2024 the company held NIS 41.2 million of cash and NIS 62.9 million of short-term deposits, together NIS 104.0 million. At the end of 2025 those numbers had fallen to NIS 21.6 million of cash and NIS 47.5 million of short-term deposits, together NIS 69.1 million. That is a NIS 34.9 million reduction in the liquid layer in a single year. Cash flow from operations remained negative at NIS 32.9 million, even if better than the NIS 41.5 million burn in 2024.

That matters because 2025 was supposed to be the year when the story started to look cleaner. If, even after the one-off GE revenue and the sharp reduction in the accounting loss, the company is still burning more than NIS 30 million from operating activities, then the balance sheet is still financing the U.S. transition rather than the business financing itself. Management does say that current cash, deposits, and anticipated operating cash flow should cover at least the next 12 months. That is reasonable. But it also says explicitly that losses and negative operating cash flow are expected to continue until product revenue reaches a sufficient level, and that additional capital may still be needed.

Another yellow flag sits in inventory. At first glance, current inventory fell from NIS 23.1 million to NIS 6.6 million. But that is only half the picture. In 2025 the company reclassified NIS 11.8 million of raw materials and NIS 1.6 million of finished goods from current to non-current inventory because the expected realization period became longer. So total inventory still stood at NIS 19.9 million at year end. That is a meaningful number against only NIS 9.48 million of ongoing revenue.

The GE link matters here as well. The company notes that assemblies equipped with long-lead items were ordered from a South Korean supplier in order to meet historical distribution obligations, at a cost of about NIS 2.9 million as of December 31, 2025, with no delivery date or payment date yet determined. On top of that, it pays quarterly interest of roughly $6 thousand. So even after the report cleaned up part of the past, not every leftover from that chapter has become cash.

From a liability perspective, the explicit pressure layers in the filing are not bank debt but IIA royalties and leases. The company carries an IIA royalty liability of NIS 9.59 million, while the maximum possible amount payable is NIS 15.6 million, and supported products are subject to a 3% royalty on sales. In addition, fixed lease obligations amounted to NIS 1.6 million, of which NIS 1.0 million is due within the next 12 months. These are not fatal numbers for a company of this size, but they do remind you that the cash pile cannot erode indefinitely.

There is one balancing point in the other direction: the balance of the main customer, Clalit, stood at NIS 4.11 million at the end of 2025, but had already been collected by the time the financial statements were approved. So commercial concentration remains very high, but in 2025 it did not spill into a collection problem.

Outlook

Five points that organize 2026

First point: 2025 was not an organic growth year. Excluding the GE component, ongoing revenue was slightly down versus 2024. That means the market now has to measure fresh growth, not a one-off cleanup.

Second point: there was no real operating improvement underneath the headline numbers. If you strip out the NIS 30.5 million GE component, 2025 operating loss would still have been roughly NIS 42.7 million, in practice slightly worse than NIS 42.2 million in 2024. That is not a technical footnote. It means the company still has not translated FDA clearance or strategic messaging into operating leverage.

Third point: 2026 begins with a clearer U.S. option. After the FDA clearance, the company had already signed two service agreements with U.S. medical centers early in 2026, and the presentation defines 2026 as the launch year in the U.S. This is the stage where the story moves from a regulatory test to a commercial test.

Fourth point: FC is starting to move from promise to a separate operating test. In the feasibility study of 48 patients, no serious adverse events were reported, and the results received in June 2025 supported comparability to standard in-clinic ultrasound. In January 2026 that was already translated into a pilot structure and a longer-term commercial framework.

Fifth point: management is already marketing an American revenue model with a meaningful SaaS layer, while service revenue is still insignificant in the financial statements. So 2026 has to prove not just device sales, but the formation of an actual recurring layer.

The U.S.: the clearance arrived, now commercialization has to follow

The FDA clearance changes the opportunity set, but it does not solve the bottleneck. The company itself frames the U.S. as the core strategic market, cites roughly 3.6 million annual births, and highlights access gaps such as 35% of U.S. counties being maternity care deserts. The presentation extends that framing into launch language: OB networks and hospitals, telehealth partnerships, employer partnerships, and an eventual model in which 40% of revenue should come from subscriptions and monitoring.

That is a logical strategic framework. But from an investor filter perspective, the question is not whether the U.S. market is large. The question is whether Pulsenmore can convert the FDA event into repeat revenue fast enough. So far, the filings do not disclose U.S. order volume, installed base, utilization, or recurring revenue that has already started to show up. That means the market will soon need more than first agreements. It will need evidence that the company can connect device, clinician, payment, and monitoring into a model that generates more than one-off hardware revenue.

FC: the second leg can open, but it is still under test

FC is probably the less priced-in part of the story, because it can expand the company beyond pregnancy into IVF and fertility preservation. The older Clalit agreement spoke about an aggregate $10.8 million framework subject to feasibility conditions and included meaningful return rights. By year end 2025, 400 devices had already been supplied, 100 of them for the feasibility study.

After year end, the more important update arrived: an 18-month pilot in which the company and Clalit may market FC directly to patients, with Beilinson NEXT support, and then five years with a 2,000-unit annual minimum and total consideration of $9 million. That is much closer to real commercialization. But practical friction remains here too: a long pilot period, return rights of up to 1,000 units per year, and the fact that the company still has not shown how the FC line translates clinical promise into revenue and cash generation.

What the market should measure over the next 2 to 4 quarters

The first test is whether the U.S. begins to produce visible revenue, not just open doors. The second is whether FC starts contributing beyond study and pilot framing. The third is whether Clalit’s share of revenue actually declines through growth elsewhere. The fourth is whether liquidity erosion starts to moderate, mainly through operating growth rather than through another accounting event.

That is why the right label for the next year is proof year. If the company shows visible international growth, the start of service revenue, and FC moving from pilot framing to orderly sales, the thesis will improve quickly. If by the end of 2026 we are still looking at roughly the same scale of ongoing revenue, the same customer concentration, and a heavy cash burn profile, the reading on the story will remain far less generous.

Risks

The first risk is customer concentration. In 2025, Clalit generated about NIS 8.82 million out of NIS 9.48 million of ongoing revenue. That is not just commercial dependence. It is dependence on the adoption pace, contract terms, and procurement behavior of a single institution.

The second risk is commercialization risk, not product risk. The product has already passed through clinical work and regulatory milestones in several markets. What has not been proven is whether the company can build a broad commercial machine outside Israel. Italy is a good example: the agreement exists, but as of the end of 2025 only 120 units had been ordered and execution was postponed.

The third risk is financing. The company is not sitting on the edge of a debt event today, but a NIS 32.9 million annual operating cash burn and a nearly NIS 35 million reduction in liquid resources shift the center of gravity toward the question of when another capital raise becomes necessary if commercialization takes longer. That is exactly why the balance sheet is a bridge, not the destination.

The fourth risk is the quality of conversion from past inventory and obligations into cash. Inventory of NIS 19.9 million, of which NIS 13.3 million is non-current, plus long-lead components that are still hanging in the system, suggest that not every shekel invested in the past will recycle quickly through sales.

The fifth risk is liquidity and market reading. A market cap of roughly NIS 67.2 million, daily turnover of about NIS 228 thousand, and short interest of only 0.45% of float do not create a deep market. That is not an operating risk, but it is a real risk of volatility and limited ability to build or unwind a position without moving the price.

Conclusions

Pulsenmore exits 2025 in a more interesting position than it was a year earlier, but not in as clean a position as the headlines suggest. The GE settlement closed an overhang, the FDA clearance finally opened the U.S., and FC is beginning to get a real commercialization structure. On the other hand, ongoing revenue barely moved, concentration remained extreme, and the balance sheet is still the main thing financing the story.

Current thesis in one line: Pulsenmore moved in 2025 from closing the GE chapter to opening the U.S. chapter, but until the new push produces repeat revenue, the report still leans more on a one-off event and existing cash than on a mature commercial engine.

What changed versus 2024 is clear: there is FDA clearance, less strategic friction from GE, a clearer FC route, and a broader base for the U.S. option. What barely changed at all is the underlying economics of the business. That is exactly why the market should now focus less on the technology story and more on the conversion of that story into revenue.

Counter-thesis: the cautious read here may still understate the option value. The company has a real regulatory and product edge, a balance sheet that still buys time, a much larger U.S. market, and FC as a second product leg. If 2026 produces even partial demand proof in the U.S. while FC starts to convert, current valuation could turn out to be low relative to the opportunity.

What could change the market’s interpretation in the short to medium term? U.S. contracts with visible volume, proof of service revenue rather than just device revenue, real FC commercialization, and a moderation in liquidity burn. What would weaken the story is another report in which ongoing revenue stays stuck, inventory does not unwind, and the company continues to finance the narrative through its cash balance.

Why does this matter? Because Pulsenmore is no longer just a regulation-and-technology story. It is entering the stage where product and regulatory advantage have to start turning into a broader business. If that does not happen within a reasonable window, the balance sheet will be carrying the story for too long.